Kit Hunter Gordon
Amministratore Delegato presso The Summit Group Ltd.
Profilo
Mr. Kit H.
Gordon is Chairman & Managing Partner at Seraphim Capital (General Partner) LLP.
Mr. Gordon also served on the board at Sirigen Group Ltd.
Posizioni attive di Kit Hunter Gordon
Società | Posizione | Inizio |
---|---|---|
Seraphim Capital (General Partner) LLP
Seraphim Capital (General Partner) LLP Investment ManagersFinance Seraphim Capital (General Partner) LLP, a subsidiary of YFM Equity Partners LLP, is a venture capital firm founded in 2006. The firm is headquartered in London, the United Kingdom. | Investitore di Private Equity | 01/09/2006 |
The Summit Group Ltd.
The Summit Group Ltd. Financial ConglomeratesFinance The Summit Group Ltd. provides investment services. The British company was founded in 1985 by Kit Hunter Gordon, who has been the CEO since then. | Amministratore Delegato | 01/01/1985 |
Resources for Autism
Resources for Autism Miscellaneous Commercial ServicesCommercial Services Resources for Autism provides social services. The non-profit company is based in London, UK. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Kit Hunter Gordon
Società | Posizione | Fine |
---|---|---|
Sirigen Group Ltd.
Sirigen Group Ltd. Chemicals: Major DiversifiedProcess Industries Harnessing the power of novel light-harvesting polymeric materials, Sirigen's amplification technology offers High Sensitivity Fluorescence™ (HSF™) detection to the Diagnostic and Life Science marketplaces. The company's versatile and HSF™ technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications. Its platform agnostic, enabling technology represents a quantum leap in detection capabilities, amplifying the sensitivity of a wide range of existing instrumentation and detection platforms by up to 100 fold. The company's technology is applicable to a diverse cross section of the biomedical industry including the $6billion drug discovery industry which can use it to test the efficacy of new drugs, the $12billion life sciences industry which can use Sirigen to develop new detection platforms, and the $35billion diagnostics industry, which can work with the company to optimise existing diagnostic techniques and to develop the next generation of diagnostic tools. Indeed the potential to deliver real time testing on miniaturised monitoring devices is close to reality. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 4 |
---|---|
Seraphim Capital (General Partner) LLP
Seraphim Capital (General Partner) LLP Investment ManagersFinance Seraphim Capital (General Partner) LLP, a subsidiary of YFM Equity Partners LLP, is a venture capital firm founded in 2006. The firm is headquartered in London, the United Kingdom. | Finance |
Sirigen Group Ltd.
Sirigen Group Ltd. Chemicals: Major DiversifiedProcess Industries Harnessing the power of novel light-harvesting polymeric materials, Sirigen's amplification technology offers High Sensitivity Fluorescence™ (HSF™) detection to the Diagnostic and Life Science marketplaces. The company's versatile and HSF™ technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications. Its platform agnostic, enabling technology represents a quantum leap in detection capabilities, amplifying the sensitivity of a wide range of existing instrumentation and detection platforms by up to 100 fold. The company's technology is applicable to a diverse cross section of the biomedical industry including the $6billion drug discovery industry which can use it to test the efficacy of new drugs, the $12billion life sciences industry which can use Sirigen to develop new detection platforms, and the $35billion diagnostics industry, which can work with the company to optimise existing diagnostic techniques and to develop the next generation of diagnostic tools. Indeed the potential to deliver real time testing on miniaturised monitoring devices is close to reality. | Process Industries |
Resources for Autism
Resources for Autism Miscellaneous Commercial ServicesCommercial Services Resources for Autism provides social services. The non-profit company is based in London, UK. | Commercial Services |
The Summit Group Ltd.
The Summit Group Ltd. Financial ConglomeratesFinance The Summit Group Ltd. provides investment services. The British company was founded in 1985 by Kit Hunter Gordon, who has been the CEO since then. | Finance |
- Borsa valori
- Insiders
- Kit Hunter Gordon